Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Lymphoma, T-Cell, Peripheral 7Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma 6Leukemia, Myeloid, Acute 6Lymphoma, T-Cell, Cutaneous 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Lung Neoplasms 4Hodgkin Disease 4Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 3Urinary Bladder Neoplasms 3Sarcoma 3Neoplasms 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Immunoblastic Lymphadenopathy 3Fallopian Tube Neoplasms 3Burkitt Lymphoma 3Thyroid Neoplasms 2

Interventions

Rituximab 112Cyclophosphamide 103fludarabine 61Doxorubicin 33Vincristine 31Etoposide 31Prednisone 30Lenalidomide 24ibrutinib 22fludarabine phosphate 21Immunotherapy, Adoptive 19Bendamustine Hydrochloride 19obinutuzumab 18Cytarabine 18pembrolizumab 16Magnetic Resonance Spectroscopy 16Bortezomib 14Specimen Handling 13Dexamethasone 13polatuzumab vedotin 12CT-P10 12venetoclax 11pirtobrutinib 11Gemcitabine 11Carboplatin 11glofitamab 10zanubrutinib 9Nivolumab 9Mycophenolic Acid 9Melphalan 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × belinostat × Clear all
NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT00413075 2015-07-08

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

Valerio Therapeutics

Phase 1 Completed
121 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Fibrosarcoma, Head and Neck Neoplasms, Hemangiosarcoma, Hodgkin Disease, Kidney Neoplasms, Leiomyosarcoma, Liposarcoma, Lung Neoplasms, Lymphoma, Mesothelioma, Otorhinolaryngologic Neoplasms, Ovarian Neoplasms, Parathyroid Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Thyroid Neoplasms, Colorectal Neoplasms, Lymphoma, B-Cell, Lymphoma, T-Cell, Adenosarcoma, Mixed Tumor, Mesodermal, Mesothelioma, Cystic, Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡